Massive Bio is a technology company.
Massive Bio has raised $17.9M across 2 funding rounds.
Massive Bio has raised $17.9M in total across 2 funding rounds.
Massive Bio has raised $17.9M in total across 2 funding rounds.
Massive Bio's investors include 8VC, GreatPoint Ventures, Jonathan Bush, Surface Ventures.
Massive Bio is an AI-driven precision oncology company that builds platforms like SYNERGY-AI and Deep Learning Clinical Trial Matching System (DLCTMS) to match cancer patients with suitable clinical trials and treatments worldwide.[1][2][3][4] It serves cancer patients, oncologists, hematologists, hospital networks, pharmaceutical companies, and contract research organizations (CROs) by solving key challenges in clinical trial access, such as inefficient matching, high screen failures, and geographic barriers, using AI for molecular profiling, NLP, computer vision, and real-time data analysis.[1][2][5] The company has demonstrated strong growth momentum, onboarding over 120,000 patients across 12 countries, partnering with 5,000 physicians, and collaborating with pharma giants like AstraZeneca, Bayer, GSK, Johnson & Johnson, Novartis, and Roche via the Precision Cancer Consortium; it adds ~6,000 patients monthly and aims for 250,000 by mid-2024.[2][3][4][5]
Massive Bio was founded in 2015 by a team of clinical, technology, and M&A executives, including CEO and Co-Founder Selin Kurnaz, PhD, and Co-Founder and Chief Medical Officer Dr. Arturo Loaiza-Bonilla.[4][5] The idea emerged from recognizing inefficiencies in cancer treatment access—existing methods often fail, and clinical trial enrollment is challenging without doctor referrals—prompting the creation of AI tools to "erase cancer from the map" by personalizing matches via Next Generation Sequencing (NGS) and big data.[1][4] Early traction came from developing end-to-end AI for confidential patient data matching, leading to HIPAA/GDPR-compliant services; by 2021, it set a 100,000-patient goal, surpassing it with 102,000+ onboarded, and expanded globally while securing an SBIR contract from the National Cancer Institute.[3][4][5]
Massive Bio rides the AI in precision oncology trend, leveraging big data and machine learning to democratize access to 16,000+ global trials amid rising cancer prevalence and demand for personalized medicine.[2][6] Timing is ideal as post-pandemic clinical trial bottlenecks—exacerbated by inefficiencies in recruitment and screening—create urgency; AI resolves these by structuring unstructured data and enabling real-world evidence, as shown in ASCO 2024 research with pharma leaders.[2][3][5] Market forces like NGS adoption, regulatory pushes for equitable care (e.g., EU trials), and pharma's need for faster enrollment favor it, positioning Massive Bio to influence the ecosystem by accelerating drug pipelines, improving outcomes, and setting standards for patient-centric AI platforms.[1][4][5]
Massive Bio is poised to dominate AI oncology matching, expanding SYNERGY-AI to drug matching, broader geographies, and 250,000+ patients by mid-2024, fueled by pharma partnerships and NCI backing.[3][4][5] Trends like multimodal AI integration, real-world data analytics, and global trial harmonization will propel growth, potentially evolving its influence from matcher to full oncology ecosystem orchestrator—bridging patients, providers, and innovators to bury cancer in history's hidden pages, as its mission envisions.[1][3]
Massive Bio has raised $17.9M across 2 funding rounds. Most recently, it raised $17.0M Series B in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $17.0M Series B | 8VC, GreatPoint Ventures, Jonathan Bush | |
| Jul 1, 2016 | $900K Seed | Surface Ventures |